BioNTech and Fosun Pharma, Takeda, AstraZeneca and Daiichi Sankyo made our news this week. (Google)
BioNTech is expanding in Asia with a planned regional headquarters and mRNA manufacturing facility in Singapore, plus a joint venture with Fosun Pharma focused on its COVID-19 vaccine in China. Takeda believes revenues from its remaining portfolio can help it pay down debt and grow into the future. Daiichi Sankyo and AstraZeneca s anti-TROP2 antibody-drug conjugate reported early tumor shrinkage data. And more.
With cash flow from selling its COVID-19 vaccine, BioNTech aims to become a “global immunotherapy powerhouse.” After setting up new operations in Europe and the U.S., the mRNA specialist is targeting Asia. It will set up a Southeast Asia regional headquarters in Singapore, accompanied by an mRNA manufacturing facility that could eventually boast an estimated annual capacity of several hundred million doses of mRNA shots.
Takeda Pharmaceutical : enregistre des résultats résilients pour l exercice 2020, accompagnés de solides marges et d un flux de trésorerie robuste ; ce qui devrait accélérer la croissance de son chiffre d affaires sous-jacent pour l exercice 2021
zonebourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zonebourse.com Daily Mail and Mail on Sunday newspapers.
Takeda Pharmaceutical Company Limited: Takeda liefert belastbare Ergebnisse für das Geschäftsjahr 2020 mit starken Margen und robustem Cashflow; Das zugrunde liegende Umsatzwachstum wird sich voraussichtlich im GJ2021 beschleunigen
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.